Top Page
HBM Holdings Ltd.
(2142)
HBM Holdings Ltd. (2142) vs. iShares MSCI Hong Kong ETF (EWH)
HBM Holdings Ltd. Business Overview & Revenue Model
HBM Holdings Ltd. Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 38.10M | 89.50M | 40.66M | 4.31M | 14.11M | Gross Profit |
| 33.61M | 87.47M | 40.53M | 4.17M | 13.66M | EBIT |
| -3.69M | 21.83M | -123.53M | -137.84M | -296.54M | EBITDA |
| -896.00K | 31.18M | -115.50M | -130.84M | -290.91M | Net Income Common Stockholders |
| 2.78M | 22.80M | -137.27M | -137.88M | -296.54M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 167.22M | 140.72M | 171.71M | 216.30M | 356.95M | Total Assets |
| 215.01M | 228.48M | 232.12M | 282.36M | 388.74M | Total Debt |
| 61.34M | 66.01M | 90.93M | 19.47M | 1.73M | Net Debt |
| -105.48M | -74.31M | -80.78M | -196.83M | -355.07M | Total Liabilities |
| 90.96M | 108.85M | 139.62M | 59.45M | 27.73M | Stockholders Equity |
| 124.45M | 119.99M | 92.83M | 223.19M | 361.19M |
| Cash Flow | Free Cash Flow | |||
| 30.44M | -21.60M | -118.40M | -139.81M | -35.99M | Operating Cash Flow |
| 30.68M | -19.12M | -99.96M | -125.61M | -35.39M | Investing Cash Flow |
| 6.55M | 28.09M | 137.59M | -76.90M | -93.53M | Financing Cash Flow |
| -10.24M | -29.14M | 70.58M | 1.59M | 357.86M |
HBM Holdings Ltd. Technical Analysis
HBM Holdings Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$6.80B | 176.83 | 1.43% | ― | 2433.62% | ― | |
60 Neutral | HK$6.69B | 36.19 | 9.52% | ― | 185.36% | ― | |
53 Neutral | $5.24B | 3.32 | -44.36% | 6.63% | 16.78% | -0.12% | |
48 Neutral | HK$6.51B | 268.62 | 2.28% | ― | -57.55% | -87.49% | |
45 Neutral | HK$9.10B | ― | -51.40% | ― | 58.75% | -1310.16% | |
42 Neutral | HK$5.29B | ― | -22.23% | ― | -14.17% | 76.00% |
HBM Holdings Ltd. Corporate Events
HBM Holdings Ltd. announced significant progress in its share repurchase program, having repurchased HK$130 million worth of shares in 2025, reflecting its commitment to enhancing shareholder value. The company has also entered into multiple strategic collaborations, including a major partnership with AstraZeneca, which could yield up to US$4.4 billion in milestone payments, underscoring its strong market positioning and potential for growth.
HBM Holdings Ltd. announced that the China National Intellectual Property Administration upheld its patent for a method of producing fully human heavy chain-only antibodies, following a challenge by Biocytogen Pharmaceuticals. This decision reinforces HBM’s intellectual property rights, allowing the company to continue leveraging its patented technology to develop innovative therapies, which could have significant implications for its market positioning and stakeholders.
HBM Holdings Ltd. announced that its subsidiary, Nona Biosciences, has entered into a license agreement with Visterra, Inc. to advance biotherapeutic treatments for immune-mediated and autoimmune diseases. This collaboration leverages Nona Biosciences’ HCAb Harbour Mice® technology, which is recognized for its reduced immunogenicity and versatility, potentially enhancing HBM Holdings’ market position in the biotechnology sector.
HBM Holdings Limited, incorporated in the Cayman Islands, announced the successful passage of all proposed resolutions during its Annual General Meeting held on June 11, 2025. Key resolutions included the adoption of financial statements, re-election of directors, auditor reappointment, and granting mandates for share issuance and repurchase. The AGM results reflect strong shareholder support for the company’s strategic decisions, potentially impacting its future operational and financial strategies.
HBM Holdings Limited has announced the appointment of Dr. Ian Yi Liu as a joint company secretary, effective June 9, 2025. Dr. Liu, who joined the company in March 2025 as a Senior Vice President and Global Head of Legal, brings extensive legal expertise and industry experience, having previously served as company secretary for Breas Medical Holdings AB and advised Shanghai Fosun Pharmaceutical. This strategic appointment is expected to enhance the company’s corporate governance and operational efficiency.
HBM Holdings Limited has announced a change in its company secretary position. Ms. Yifan Gao will cease to be a joint company secretary due to a change in her work arrangements, effective May 26, 2025. She has confirmed no disagreements with the board. Mr. Wing Yat Christopher Lui will continue as the sole company secretary, possessing the necessary qualifications and experience. The board expressed gratitude for Ms. Gao’s contributions during her tenure.
HBM Holdings Ltd. has announced that its first-in-human Phase 1 clinical study design for MesoC2, a mesothelin-targeting ADC, will be presented at the 2025 ASCO Annual Meeting by its collaborator, Pfizer. MesoC2, developed using HBM’s proprietary platforms, is being tested for safety and efficacy in patients with advanced solid tumors, potentially positioning it as a globally best-in-class therapeutic option.
HBM Holdings Ltd. announced the grant of 4,875,000 share options to two non-connected employees under its Share Option Scheme. The options, priced at HK$8.60 per share, come with a 10-year exercise period and vesting conditions tied to individual performance appraisals. This initiative aims to incentivize employees to enhance the company’s value, aligning their interests with those of shareholders.
HBM Holdings Ltd. has issued a clarification regarding an error in the English version of its proxy form for the upcoming annual general meeting on June 11, 2025. The error involved the re-election of Dr. Xiaoping Ye as an independent non-executive director. The company has released a revised proxy form to ensure shareholders can vote accurately on this resolution. This announcement aims to maintain transparency and ensure proper governance practices, highlighting the company’s commitment to its shareholders.
HBM Holdings Limited has announced its upcoming annual general meeting, scheduled to take place on June 11, 2025, in Shanghai, China. The meeting will address several key resolutions, including the adoption of the company’s audited financial statements for 2024, the re-election of two independent non-executive directors, and the re-appointment of Ernst & Young as the company’s auditor. Additionally, the board will seek authorization to issue new shares and fix directors’ remuneration, which could impact the company’s capital structure and governance.
HBM Holdings Ltd. has announced a plan to repurchase up to HK$200 million worth of its shares in the open market, as part of its ongoing strategy to enhance shareholder value. The company believes its current trading price undervalues its intrinsic worth and aims to demonstrate confidence in its business prospects through this initiative, while maintaining a solid financial position.
HBM Holdings Ltd. has successfully completed the issuance of 76,271,762 subscription shares to AstraZeneca Holdings under a general mandate, raising approximately US$105.3 million in gross proceeds. The net proceeds will be primarily used for pre-clinical discovery and research and development, with a portion allocated for working capital and general corporate purposes, positioning the company for future growth and development in the biotechnology sector.
HBM Holdings Ltd. announced its annual results for 2024, highlighting a significant decrease in revenue from $89.5 million in 2023 to $38.1 million in 2024, alongside a reduction in research and development expenses. The company reported a profit of $2.7 million for the year. Key business developments include the acceptance of a Biologics License Application for Batoclimab in China, the approval of an IND application for HBM9378 for COPD, and ongoing clinical trials for other products, indicating a strategic focus on advancing its therapeutic pipeline.
HBM Holdings Ltd. has announced a strategic collaboration with AstraZeneca, which includes a share subscription agreement and a partnership to develop next-generation multi-specific antibodies. The agreement will see AstraZeneca subscribe to 9.15% of HBM’s shares, raising approximately US$105.3 million for HBM’s research and development and operational needs. The collaboration is expected to enhance HBM’s position in the biopharmaceutical industry by leveraging AstraZeneca’s global drug development expertise, potentially leading to significant advancements in antibody therapeutics. This partnership also involves establishing an innovation center in Beijing and could result in up to US$4.4 billion in milestone payments for HBM, underscoring the potential impact on the company’s growth and market presence.